Clinical Trial

Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

Name: Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer — clinical trial record (NCT07104110)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This study is designed to determine if experimental treatment with QLH12016 in combination with novel hormonal agent (NHA) is safe, tolerable, and has anti-cancer activity in patients with advanced prostate cancer.

Trial Details

NCT Number	NCT07104110
Lead Sponsor	Qilu Pharmaceutical Co., Ltd.
Conditions	Prostatic Neoplasms
Enrollment	50 participants
Start Date	2025-10
Primary Completion	2027-10 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2025-08-05